Halozyme Therapeutics, Inc. (NASDAQ:HALO) registered a 3.81% increase, still its new closing price is 72.27% up from the company’s 1 year high of 14.38.It posted 1.78% gains in previous 5 sessions and is now the subject of 1 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 1 sells versus 3 buy or better ratings. The 9 stock analysts following this company have an average price target at $14.84, with individual PT in the $6.75-$20.00 range. The shares moved at $11.99, implying that brokerage firms see shares gaining about 47.84% in twelve months time.
Halozyme Therapeutics, Inc. (HALO) SEC Form 4 News
The stock is getting much attention these days as insiders are adding shares while they posted a 21.36% rise year to date. A CFO at Halozyme Therapeutics, Inc. (HALO) acquired shares in a transaction closed on Thursday August 20, 2015. Stelzer Laurie bought 10,000 shares in the company at $17.24 each and collected $172,000 in proceeds. Stelzer Laurie now owns 10,000 shares in the company after this transaction. A CFO in the company, Stelzer Laurie, disclosed a transaction on Thursday August 20, 2015 that ended up paying $172,000 from the purchase of 10,000 shares at $17.24 per share.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Upcoming Results on Tap
Halozyme Therapeutics, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.23 in that period. Sales during the quarter are predicted to arrive at $34.9 million.
Earnings surprise history: Last quarter, the company posted approximately $31.85 million in revenue and EPS of $-0.23. The mean forecast was for $33.86 million and $-0.27 a share, respectively. One quarter earlier, revenue for the stock was at $33.34 million, with earnings at $-0.21/share.
Halozyme Therapeutics, Inc. (HALO) Brokerage Update
Halozyme Therapeutics, Inc. (HALO) is in Citigroup’s research list so their analyst rating change is noteworthy. These shares were downgraded to Neutral from Buy by Citigroup, according to news reported on Friday January 06, 2017.Another important research note was issued by UBS on Thursday June 12, 2014.The firm upgraded HALO to Buy from Neutral. Over the last six months and over the last three months, the shares of Halozyme Therapeutics, Inc. (HALO), have changed 19.54% and 38.93%, respectively.